These in vitro findings suggest that, MSS CRC patients, who are more radioresistant, may require HDAC inhibitors to block the activity of the NuRD complex and restore p21 promoter acetylation, thereby resulting in enhanced p21 expression, and inducing sensitization to CCRT treatment. This evidence concerns the gene HDAC9 and colorectal carcinoma.